Active Substance: adefovir dipivoxil
Common Name: adefovir dipivoxil
ATC Code: J05AF08
Marketing Authorisation Holder: Gilead Sciences International Ltd.
Active Substance: adefovir dipivoxil
Authorisation Date: 2003-03-06
Therapeutic Area: Hepatitis B, Chronic
Pharmacotherapeutic Group: Antivirals for systemic use
Hepsera is indicated for the treatment of chronic hepatitis B in adults with:
- compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis;
- decompensated liver disease.
What is Hepsera?
Hepsera is a medicine that contains the active substance adefovir dipivoxil. It is available as white, round tablets (10 mg).
What is Hepsera used for?
Hepsera is used to treat adult patients with chronic (long-term) hepatitis B (a disease of the liver due to infection with the hepatitis-B virus). It is used in patients with:
- compensated liver disease (when the liver is damaged but functions normally), who also show signs that the virus is still multiplying, and have signs of liver damage (raised levels of the liver enzyme ‘alanine aminotransferase’ [ALT] and signs of damage when liver tissue is examined under a microscope);
- decompensated liver disease (when the liver is damaged and does not function normally).
The medicine can only be obtained with a prescription.
How is Hepsera used?
Treatment with Hepsera should be started by a doctor who has experience in the management of chronic hepatitis B. The recommended dose is 10 mg once a day, taken with or without food. The duration of treatment depends on the patient’s condition and response to treatment. These should be monitored every six months. Patients who have problems with their kidneys should take Hepsera less frequently.
Hepsera is not recommended for use in patients with severe kidney disease or who are on dialysis (a blood clearing technique) – its use should only be considered in these patients if its potential benefits are greater than its potential risks.
Patients whose disease is caused by a virus that is resistant (does not respond) to lamivudine (another antiviral medicine) should not take Hepsera on its own, to reduce the risk of resistance to Hepsera developing. These patients should take Hepsera in combination with lamivudine or consider other treatments. A change to treatment should also be considered if levels of the virus remain high after a year of treatment with Hepsera on its own.
For more information, see the summary of product characteristics (also part of the EPAR).
How does Hepsera work?
The active substance in Hepsera, adefovir dipivoxil, is a ‘prodrug’ that is converted into adefovir in the body. Adefovir is an antiviral belonging to the class ‘nucleoside analogues’. Adefovir interferes with the action of a viral enzyme called DNA polymerase, which is involved in the formation of viral DNA. Adefovir stops the virus making DNA and prevents it from multiplying and spreading.
How has Hepsera been studied?
Hepsera has been studied in two main studies, in which it was compared with placebo (a dummy treatment). The first study included 511 patients who were ‘HBeAg-positive’ (infected with the common type of the hepatitis-B virus) and the second included 184 patients who were ‘HBeAg-negative’ (infected with a virus that has mutated [changed], leading to a form of chronic hepatitis B that is more difficult to treat). In both studies, the effectiveness was measured by looking at how the liver damage had evolved after 48 weeks of treatment using a liver biopsy (when a sample of liver tissue is taken and examined under a microscope).
What benefit has Hepsera shown during the studies?
Hepsera was more effective than placebo in slowing down the progression of liver disease. Among those who took Hepsera, 53% of the HBeAg-positive and 64% of the HBeAg-negative patients had an improvement in liver damage as assessed in a biopsy, compared with 25% and 33%, respectively, in the patients who took placebo.
What is the risk associated with Hepsera?
The most common side effects with Hepsera (seen in more than 1 patient in 10) are raised creatinine (a marker of kidney problems) and asthenia (weakness). For the full list of all side effects reported with Hepsera, see the package leaflet.
Hepsera should not be used in people who may be hypersensitive (allergic) to adefovir dipivoxil or any of the other ingredients.
Why has Hepsera been approved?
The Committee for Medicinal Products for Human Use (CHMP) decided that Hepsera’s benefits are greater than its risks for the treatment of chronic hepatitis B in adults with compensated liver disease with evidence of active viral replication, persistently elevated serum ALT levels and histological evidence of active liver inflammation and fibrosis, and in adults with decompensated liver disease. The Committee recommended that Hepsera be given marketing authorisation.
Other information about Hepsera
The European Commission granted a marketing authorisation valid throughout the European Union for Hepsera to Gilead Sciences International Limited on 6 March 2003. The marketing authorisation was renewed on 6 March 2008.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.